secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K/A
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001999371-24-009003
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix expects $50M non-cash impairment on decommissioned ADC facility in Q2 2024
--------------------------------------------------------------------------------

- Non-cash impairment charge of ~$50M to be recognized in Q2 2024 financial statements.
- Facility is a 45,000 sq ft bio-safety level-2 plant in Dartmouth, MA, previously intended for live-virus vaccine manufacturing.
- Impairment assumes general industrial use, not GMP; equipment appraised; brokerage firm retained to find buyer.
- Company states impairment will not affect future operations, liquidity, or cash flows.
- Decommissioning aligns with strategic focus on Tonmya (TNX-102 SL) for fibromyalgia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/0001999371-24-009003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/tnxp-8ka_072424.htm
  HTML page:      https://secwatch.observer/filing/0001999371-24-009003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer